LillyDirect Zepbound Cost: What UK Patients Need to Know

LillyDirect Zepbound cost is a search term driven largely by US patients accessing tirzepatide through Eli Lilly's self-pay platform — but the picture for UK patients is fundamentally different. Zepbound is not licensed or commercially available in the UK; the equivalent licensed medicine here is Mounjaro (tirzepatide), regulated by the MHRA. A UK version of LillyDirect launched in June 2026 as a dispensing and delivery service, not a self-pay price list. This article explains what LillyDirect means for UK patients, how Mounjaro is accessed and priced privately, and what NHS routes may be available.

What Is LillyDirect and How Does It Work in the UK?

UK LillyDirect, launched June 2026, is a dispensing and delivery service for private Mounjaro prescriptions only — it does not prescribe or set prices, and Zepbound is not licensed in the UK.

LillyDirect is a patient services platform from Eli Lilly, the company behind tirzepatide, the active ingredient in both Mounjaro (licensed in Great Britain for type 2 diabetes and weight management) and Zepbound (a US-only brand for chronic weight management and obstructive sleep apnoea). In the US, LillyDirect lets eligible patients access these medicines through a network of telehealth providers and, in some cases, on a self-pay basis.

For UK readers, the important update is this: LillyDirect did not operate in the UK when it first launched, but since around 25 June 2026 a UK version exists. It works very differently from the US service. In the UK, LillyDirect is a dispensing and delivery service only. It does not prescribe and it does not set a self-pay price. A UK-regulated healthcare provider must first issue a private prescription for Mounjaro, and Lilly's UK dispensing partners (at launch, Pharmacy2U and Onescript) then fulfil and deliver it. Because there is no US-style self-pay counter in the UK, the phrase 'LillyDirect Zepbound cost' does not translate into a single UK price.

In Great Britain, tirzepatide is marketed under the single brand name Mounjaro and holds a licence from the Medicines and Healthcare products Regulatory Agency (MHRA) for both type 2 diabetes and chronic weight management in eligible adults. The prescribing information is available via the Electronic Medicines Compendium (EMC) SmPC for Mounjaro. The licensing position in Northern Ireland may differ slightly; patients there should ask their GP or pharmacist.

Zepbound is not licensed or commercially available in the UK. UK patients and clinicians should therefore focus on the licensed UK product, Mounjaro, and on regulated UK pathways rather than trying to access US-based self-pay services or import medicines. The MHRA advises that obtaining prescription-only medicines from overseas websites or by mail order is unsafe and may be unlawful.^[13] UK private services should be registered with the Care Quality Commission (CQC) and use GMC-registered prescribers, and online dispensing pharmacies should be registered with the General Pharmaceutical Council (GPhC).

Zepbound Pricing in the US and Why It Does Not Apply in the UK

US LillyDirect self-pay Zepbound prices are not transferable to the UK, where tirzepatide is sold as Mounjaro and priced by the prescribing service and pharmacy, not by Eli Lilly.

In the United States, Zepbound is supplied as single-dose vials and as prefilled KwikPen autoinjectors, and Eli Lilly offers it on a self-pay basis through LillyDirect at prices it positions as lower than standard retail pharmacy pricing. US self-pay pricing changes frequently (it has been revised more than once), so any specific dollar figure quoted online can quickly become outdated. Patients wanting current US figures should check the official LillyDirect or Eli Lilly website. These US prices are referenced here only for context and do not apply to UK patients.

For UK readers, US prices are not transferable, and not only because of the currency. The UK does not use the same insurance-based or direct-to-consumer self-pay pharmaceutical model, and the new UK LillyDirect service is a delivery layer rather than a self-pay price list. Attempting to import Zepbound from the US for personal use raises serious concerns under MHRA regulations on importing prescription-only medicines, as well as risks around product authenticity, cold-chain integrity, and patient safety.

In the UK, the cost of tirzepatide (as Mounjaro) through a private prescription varies considerably depending on the dose, the provider, and whether follow-up appointments, monitoring tests, and dispensing charges are included. This is true whether the medicine is delivered through UK LillyDirect's dispensing partners or another regulated pharmacy, because the price is set by the prescribing service and pharmacy, not by Lilly. Patients should request a full, itemised breakdown of all costs (including VAT where applicable) before committing. Transparent, all-inclusive pricing is a good marker of a reputable service, and figures should be confirmed directly with individual CQC-registered providers, as they change over time.

NHS and Private Prescribing Options for Tirzepatide in the UK

NHS tirzepatide access is limited to specialist weight management services under NICE TA1026; private prescribing is available through CQC-registered providers following MHRA licence thresholds.

In Great Britain, tirzepatide (Mounjaro) is licensed by the MHRA for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or above, or 27 kg/m² or above (and below 30) in the presence of at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea).^[1][2] These are the licence thresholds and they apply to private prescribing.

NHS-funded access is separate and more restrictive. NICE technology appraisal TA1026 recommends tirzepatide for managing overweight and obesity only for adults with a BMI of at least 35 kg/m² and at least one weight-related comorbidity (with a lower BMI threshold for some ethnic groups), delivered through specialist weight management services and phased in over several years, prioritising the highest clinical need first. This means NHS weight-management access is currently limited and is not universally available through a standard GP referral. (For type 2 diabetes, tirzepatide is recommended separately under NICE TA924.)

Patients who meet the NHS criteria may be referred to a specialist weight management service. Availability varies significantly by Integrated Care Board (ICB) area, and many patients face long waits or find their local service is not yet funded to prescribe tirzepatide routinely.

For those who do not qualify for NHS treatment, or who wish to start sooner, private prescribing is a legal and increasingly common route, following the SmPC licence thresholds above. A number of regulated UK clinics and online services prescribe Mounjaro privately after a thorough clinical assessment. Since June 2026, one of the dispensing options for a private Mounjaro prescription is Eli Lilly's own LillyDirect service (via Pharmacy2U or Onescript), though many other GPhC-registered pharmacies dispense it too. Patients should ensure any private provider:

• Is registered with the Care Quality Commission (CQC)

• Employs GMC-registered prescribers

• Uses a GPhC-registered dispensing pharmacy

• Conducts appropriate baseline assessments (for example blood pressure, HbA1c, renal function, weight and BMI)

• Offers ongoing monitoring and clinical support throughout treatment

Important safety notes from the Mounjaro SmPC: Tirzepatide should not be used during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment.^[6][8] Tirzepatide may reduce the absorption of oral contraceptives; women using oral contraceptive pills should switch to a non-oral method or add a barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase. Patients taking insulin or a sulfonylurea alongside tirzepatide have an increased risk of hypoglycaemia, and dose adjustments may be needed.^[6][8] Discuss these points with your prescriber before starting.

Financial Support Schemes and Savings Programmes Available

No UK manufacturer-led savings programme exists for Mounjaro; patients can manage costs by comparing CQC-registered providers, optimising dose, and exploring multi-month plans with adequate clinical oversight.

Unlike the US, where Eli Lilly runs self-pay pricing and savings programmes for Zepbound, there is no equivalent manufacturer-led patient savings programme for Mounjaro in the UK at the time of writing. The launch of UK LillyDirect in June 2026 added a manufacturer-run delivery option, but it did not introduce a subsidised or discounted price: the cost of a private Mounjaro prescription is still set by the prescribing service and pharmacy.

There are practical ways UK patients can manage the cost of private tirzepatide treatment:

• Comparing providers: prices differ between clinics, digital platforms, and dispensing pharmacies. Reputable, CQC-registered services should provide transparent, all-inclusive pricing covering consultations, monitoring, and dispensing.

• Dose optimisation: not everyone needs the highest dose. Starting low and titrating slowly, as clinically appropriate and in line with the SmPC, may reduce monthly costs.

• Multi-month plans: some providers offer packages at a lower per-unit cost. Ensure these include adequate clinical oversight, and avoid long-term prepayment without clear cancellation and refund terms and ongoing clinical review.

• Health insurance: UK private health insurance rarely covers weight-management medicines, but it is worth checking your policy terms directly with your insurer.

Be cautious of heavily discounted tirzepatide from unverified online sources. The MHRA has issued safety alerts about counterfeit and falsified weight-loss injections circulating online, and buying from unregulated sources risks incorrect dosing, contamination, or entirely different substances. To verify an online pharmacy, check the GPhC online register; to verify a clinic or prescribing service, check the CQC provider register.

If you think you have experienced a side effect from any medicine, including tirzepatide, report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Speaking to a UK Clinician About Tirzepatide Affordability

A GP can assess NHS eligibility and referral options; a qualified clinician can also review clinical suitability, titration schedule, monitoring needs, and alternative treatments such as semaglutide.

If you are considering tirzepatide for weight management and are worried about cost, the most useful first step is an honest conversation with a qualified UK clinician. Your GP is a good starting point: they can assess whether you meet the criteria for NHS referral to a specialist weight management service, which would significantly reduce or remove out-of-pocket costs.

If NHS access is not currently available in your area, or you are considering private treatment, a clinician can help you understand the full picture, including:

• Whether tirzepatide is clinically appropriate for you, including any contraindications or cautions (for example a history of pancreatitis or severe gastrointestinal disease). Note that, unlike the US label, a personal or family history of medullary thyroid carcinoma or MEN2 is not a contraindication in the UK Mounjaro SmPC, though you should still tell your prescriber about any thyroid concerns.

• The dosing and titration schedule: the usual starting dose of Mounjaro is 2.5 mg once weekly, titrated at four-weekly intervals up to a maximum of 15 mg once weekly, as tolerated and as directed by your clinician (refer to the EMC SmPC for full details).

• The expected duration of treatment and the associated long-term costs.

• Monitoring requirements such as blood tests, blood pressure checks, and follow-up consultations.

• Alternative options, such as other GLP-1 receptor agonists (for example semaglutide as Wegovy) that may be more accessible or affordable for you.

Tirzepatide is a dual GIP and GLP-1 receptor agonist, acting through two complementary hormonal pathways to reduce appetite, slow gastric emptying, and improve metabolic function.^[6][8] Trial data from the SURMOUNT programme (published in the New England Journal of Medicine and related journals) show significant weight-loss outcomes, but the medicine works best alongside dietary change, increased physical activity, and behavioural support.

If during treatment you experience concerning symptoms, such as severe or persistent abdominal pain, persistent nausea or vomiting, signs of pancreatitis, a rapid or irregular heart rate, or symptoms of low blood sugar (if also taking insulin or a sulfonylurea), contact your prescriber promptly. For urgent advice call NHS 111, and in a life-threatening emergency call 999 or go to A&E. Affordability matters, but it should never come at the expense of safe, supervised care.

Frequently Asked Questions